Skip to Content
Learn about Mavyret, a treatment for Hepatitis C

Drug interactions between Harvoni and Viekira Pak

Results for the following 2 drugs:
Harvoni (ledipasvir/sofosbuvir)
Viekira Pak (dasabuvir/ombitasvir/paritaprevir/ritonavir)

Interactions between your drugs

There were no interactions found in our database between Harvoni and Viekira Pak - however, this does not necessarily mean no interactions exist. Always consult with your doctor or pharmacist.

Harvoni

A total of 179 drugs (774 brand and generic names) are known to interact with Harvoni.

Viekira Pak

A total of 888 drugs (4675 brand and generic names) are known to interact with Viekira Pak.

Drug and food interactions

Moderate

ritonavir food

Applies to: Viekira Pak (dasabuvir / ombitasvir / paritaprevir / ritonavir)

Ritonavir should be taken with food to lessen gastrointestinal side effects. It is important that you take this medication exactly as prescribed by your doctor. Do not change your treatment or stop treatment without first talking to your doctor.

Switch to professional interaction data

Moderate

paritaprevir food

Applies to: Viekira Pak (dasabuvir / ombitasvir / paritaprevir / ritonavir)

Food significantly increases the absorption of paritaprevir. You should take each dose of paritaprevir with a meal. Taking it on an empty stomach may lead to inadequate blood levels and reduced effectiveness of the medication.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

NS5A inhibitors

Therapeutic duplication

The recommended maximum number of medicines in the 'NS5A inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'NS5A inhibitors' category:

  • ledipasvir/sofosbuvir
  • dasabuvir/ombitasvir/paritaprevir/ritonavir

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide